SEQ Listing.ST25 SEQUENCE LISTING

```
<110> Valentis, Inc.
       Kumar, Sanjeev
<120>
       Polymer Modified Anti-Angiogenic Serpins
<130>
       213-0086US
<150>
       us 60/396,786
       2002-07-18
<151>
<160>
       2
<170>
       PatentIn version 3.2
<210>
       1
       418
<211>
<212>
       PRT
<213>
       Homo sapiens
<220>
<221>
       Human PEDF
<222>
       (1)..(418)
<220>
<221>
<222>
       predicted signal sequence
       (1)..(20)
<223>
       Cleavage site might be C or Q
<220>
<221>
       predicted mature polypeptide
<222>
       (21)..(418)
<223>
       Cleavage site might be C or Q, thus first amino acid might be Q
<220>
<221>
       predicted neurotropic activity and receptor binding
<222>
       (88)..(121)
<220>
<221>
       collagen binding domain
<222>
       (134)...(163)
<220>
<221>
       free cysteine
<222>
       (261)...(261)
<220>
<221>
       rcl in italics from p14 - p10'
<222>
       (369)..(392)
<223>
       Cleavage site predicted to be L/T
<400> 1
Met Gln Ala Leu Val Leu Leu Cys Ile Gly Ala Leu Leu Gly His
Ser Ser Cys Gln Asn Pro Ala Ser Pro Pro Glu Glu Gly Ser Pro Asp
```

Pro Asp Ser Thr Gly Ala Leu Val Glu Glu Glu Asp Pro Phe Phe Lys Val Pro Val Asn Lys Leu Ala Ala Val Ser Asn Phe Gly Tyr Asp 50 60 Leu Tyr Arg Val Arg Ser Ser Met Ser Pro Thr Thr Asn Val Leu Leu 65 70 75 80 Ser Pro Leu Ser Val Ala Thr Ala Leu Ser Ala Leu Ser Leu Gly Ala 85 90 95 Glu Gln Arg Thr Glu Ser Ile Ile His Arg Ala Leu Tyr Tyr Asp Leu 100 105 110 Ile Ser Ser Pro Asp Ile His Gly Thr Tyr Lys Glu Leu Leu Asp Thr 115 120 125 Val Thr Ala Pro Gln Lys Asn Leu Lys Ser Ala Ser Arg Ile Val Phe 130 135 Glu Lys Lys Leu Arg Ile Lys Ser Ser Phe Val Ala Pro Leu Glu Lys 150 155 160Ser Tyr Gly Thr Arg Pro Arg Val Leu Thr Gly Asn Pro Arg Leu Asp 165 170 175 Leu Gln Glu Ile Asn Asn Trp Val Gln Ala Gln Met Lys Gly Lys Leu 180 185 190 Ala Arg Ser Thr Lys Glu Ile Pro Asp Glu Ile Ser Ile Leu Leu Leu 195 200 205 Gly Val Ala His Phe Lys Gly Gln Trp Val Thr Lys Phe Asp Ser Arg 210 215 220 Lys Thr Ser Leu Glu Asp Phe Tyr Leu Asp Glu Glu Arg Thr Val Arg 225 230 235 240 Val Pro Met Met Ser Asp Pro Lys Ala Val Leu Arg Tyr Gly Leu Asp 245 250 255 Ser Asp Leu Ser Cys Lys Ile Ala Gln Leu Pro Leu Thr Gly Ser Met 260 265 270 Ser Ile Ile Phe Phe Leu Pro Leu Lys Val Thr Gln Asn Leu Thr Leu 275 280 285 280 Page 2

Ile Glu Glu Ser Leu Thr Ser Glu Phe Ile His Asp Ile Asp Arg Glu 290 295 300 Leu Lys Thr Val Gln Ala Val Leu Thr Val Pro Lys Leu Lys Leu Ser Tyr Glu Gly Glu Val Thr Lys Ser Leu Gln Glu Met Lys Leu Gln Ser Leu Phe Asp Ser Pro Asp Phe Ser Lys Ile Thr Gly Lys Pro Ile Lys 340 345 350 Leu Thr Gln Val Glu His Arg Ala Gly Phe Glu Trp Asn Glu Asp Gly Ala Gly Thr Thr Pro Ser Pro Gly Leu Gln Pro Ala His Leu Thr Phe Pro Leu Asp Tyr His Leu Asn Gln Pro Phe Ile Phe Val Leu Arg Asp Thr Asp Thr Gly Ala Leu Leu Phe Ile Gly Lys Ile Leu Asp Pro Arg Gly Pro <210> 2 375 <211> <212> PRT <213> Homo sapiens <220> <221> Human Maspin (1)..(375) <222> <223> No canonical signal sequence <220> <221> putative collagen binding domain <222> (84)..(112)<220> <221> ER retention domain <222> (327)..(350)R/I predicted P1 protease cleavage site <400> 2 Met Asp Ala Leu Gln Leu Ala Asn Ser Ala Phe Ala Val Asp Leu Phe

Lys Gln Leu Cys Glu Lys Glu Pro Leu Gly Asn Val Leu Phe Ser Pro 20 25 30 Ile Cys Leu Ser Thr Ser Leu Ser Leu Ala Gln Val Gly. Ala Lys Gly 40 45 Asp Thr Ala Asn Glu Ile Gly Gln Val Leu His Phe Glu Asn Val Lys 50 55 60 Asp Ile Pro Phe Gly Phe Gln Thr Val Thr Ser Asp Val Asn Lys Leu 70 75 80 Ser Ser Phe Tyr Ser Leu Lys Leu Ile Lys Arg Leu Tyr Val Asp Lys 85 90 95Ser Leu Asn Leu Ser Thr Glu Phe Ile Ser Ser Thr Lys Arg Pro Tyr 100 105 110 Ala Lys Glu Leu Glu Thr Val Asp Phe Lys Asp Lys Leu Glu Glu Thr 115 120 125 Lys Gly Gln Ile Asn Asn Ser Ile Lys Asp Leu Thr Asp Gly His Phe 130 135 140 Glu Asn Ile Leu Ala Asp Asn Ser Val Asn Asp Gln Thr Lys Ile Leu 145 150 155 160 Val Val Asn Ala Ala Tyr Phe Val Gly Lys Trp Met Lys Lys Phe Pro 165 170 175 Glu Ser Glu Thr Lys Glu Cys Pro Phe Arg Leu Asn Lys Thr Asp Thr 180 185 190 Lys Pro Val Gln Met Met Asn Met Glu Ala Thr Phe Cys Met Gly Asn 195 200 205 Ile Asp Ser Ile Asn Cys Lys Ile Ile Glu Leu Pro Phe Gln Asn Lys 210 215 220 His Leu Ser Met Phe Ile Leu Leu Pro Lys Asp Val Glu Asp Glu Ser 225 230 235 240 Thr Gly Leu Glu Lys Ile Glu Lys Gln Leu Asn Ser Glu Ser Leu Ser 245 250 255 Gln Trp Thr Asn Pro Ser Thr Met Ala Asn Ala Lys Val Lys Leu Ser 260 265 270 Page 4

Ile Pro Lys Phe Lys Val Glu Lys Met Ile Asp Pro Lys Ala Cys Leu 275 280 285

Glu Asn Leu Gly Leu Lys His Ile Phe Ser Glu Asp Thr Ser Asp Phe 290 295 300

Ser Gly Met Ser Glu Thr Lys Gly Val Ala Leu Ser Asn Val Ile His 305 310 315 320

Lys Val Cys Leu Glu Ile Thr Glu Asp Gly Gly Asp Ser Ile Glu Val 325 330 335

Pro Gly Ala Arg Ile Leu Gln His Lys Asp Glu Leu Asn Ala Asp His 340 345

Pro Phe Ile Tyr Ile Ile Arg His Asn Lys Thr Arg Asn Ile Ile Phe 355 360 365

Phe Gly Lys Phe Cys Ser Pro 370 375